Clinical trial · Observational
A Study of Brentuximab Vedotin in Adults With CD30-positive Lymphoma
Observational, Non-interventional, Multicenter Study Aimed at Collecting Prospective Data Related to Study Safety and Effectiveness in Real Clinical Practice in Patients With CD30+ Lymphoma (BRAVE Study)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Participants with CD30-positive lympoma will be treated with brentuximab vedotin according to their clinic's standard practice. The main aim of this study is to collect information on any side effects from treatment with brentuximab vedotin. Other aims are to collect information on how brentuximab vedotin is used to treat these participants and the outcomes of these participants.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| No Intervention | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Participants with CD30-positive Lymphoma
- description
- All participants diagnosed with CD30-positive lymphoma who are receiving or will recieve brentuximab vedotin will be observed prospectively over 24-month period, unless withdrawal of informed consent, lost or death, whichever comes first.
- interventionNames
- Other: No Intervention
Primary outcomes (1)
- measure
- Number of Participants Reporting one or More Serious Adverse Events (SAEs)
- timeFrame
- Up to 4 years
Secondary outcomes (13)
- measure
- Number of Participants Reporting one or More Adverse Events (AEs)
- timeFrame
- Up to 4 years
- measure
- Number of Participants Reporting one or More Adverse Drug Reactions (ADRs)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Undergoing treatment with brentuximab vedotin (of less than 3 months from initial treatment with brentuximab vedotin) or to be received with brentuximab vedotin. 2. CD30-positive lymphoma by INV (any CD30 expression) Exclusion Criteria: 1\. Who currently participates in or with plan to participate in any interventional clinical trial.
References
Publications (0)
Data not yet available